Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead de­vel­op­ment

Tom Reil­ly

→ Mired in flag­ging sales for Vas­cepa, the harsh re­al­i­ties of the cur­rent cli­mate in biotech have hit Amarin as they slice 40% of the work­force — the ma­jor­i­ty of those cuts com­ing from the US com­mer­cial team. And the res­ig­na­tion of CFO Michael Kalb has led Amarin to in­stall Tom Reil­ly as his re­place­ment, ef­fec­tive June 20. Reil­ly had been fi­nance chief at Cara Ther­a­peu­tics since Oc­to­ber 2020; af­ter 14 years of fi­nan­cial roles at No­var­tis, he was Al­ler­gan’s head of fi­nance for the US gen­er­al med­i­cines unit from 2017-20. Un­der CEO Karim Mikhail, who suc­ceed­ed John Thero last year, Amarin hopes the job re­duc­tion will save them $100 mil­lion in the next year.

Myr­i­am Mendi­la

→ The same day that Cure­Vac inked a small deal to buy Frame Can­cer Ther­a­peu­tics for €32 mil­lion ($34 mil­lion), the Ger­man mR­NA play­er al­so dis­closed that chief de­vel­op­ment of­fi­cer Klaus Ed­vard­sen is on his way out on June 30. Big Phar­ma vet Myr­i­am Mendi­la will take over on Feb. 1, 2023, and Ul­rike Gnad-Vogt — Cure­Vac’s SVP area head on­col­o­gy — will bridge the gap in Ed­vard­sen’s place. Mendi­la’s on­col­o­gy chops will come in handy here in light of the buy­out: The world­wide head of med­ical af­fairs and CMO, on­col­o­gy at No­var­tis since 2017, she al­so led glob­al med­ical af­fairs at Roche and US med­ical af­fairs at Genen­tech.

“The ad­di­tion of Frame’s tech­nol­o­gy and tal­ent to Cure­Vac’s on­col­o­gy re­search com­ple­ments our abil­i­ty to iden­ti­fy and val­i­date promis­ing neoanti­gens for our mR­NA can­cer vac­cine pro­grams,” Cure­Vac CEO Franz-Wern­er Haas said of the M&A deal.

Ed­ward Con­ner

→ As Ed­ward Con­ner be­comes CMO of Third Har­mon­ic Bio, an in­flam­ma­to­ry dis­ease biotech with $155 mil­lion worth of fund­ing in the hop­per, chief Na­tal­ie Holles said in a state­ment that she’s “thrilled to be work­ing with Ed again.” Con­ner served as site lead and di­vi­sion head of med­ical and de­vel­op­ment at Au­dentes (now Astel­las Gene Ther­a­pies) when Holles was CEO. Con­ner makes this quick re­turn to Peer Re­view af­ter tak­ing the CMO gig at Lo­can­abio in Ju­ly 2021.

Kurt Gunter

→ With its lead pro­gram in Phase I/II tri­als for ENPP1 and ABCC6 de­fi­cien­cies, In­ozyme has tapped Kurt Gunter as CMO. For the last year, Gunter took on the roles of CMO, cell ther­a­py and head of reg­u­la­to­ry af­fairs at Athenex, feel­ing the pinch of the bear mar­ket with a bud­get over­haul that in­clud­ed an undis­closed num­ber of lay­offs. A Hos­pi­ra vet, Gunter was the med­ical chief at Ku­ur Ther­a­peu­tics be­fore he joined Athenex last spring.

Con­se­quent­ly, Dar­rel Co­hen has an­swered the call to suc­ceed Gunter as CMO, cell ther­a­py at Athenex af­ter a year as the med­ical chief of Biosight. Co­hen was VP of late-phase clin­i­cal de­vel­op­ment at Pfiz­er On­col­o­gy, but left his post in 2019 to lead clin­i­cal de­vel­op­ment at EU­SA Phar­ma.

Frank Karbe

→ San Fran­cis­co-based Bet­ter Ther­a­peu­tics is hand­ing over the reins of the com­pa­ny to Frank Karbe, who will be­gin as pres­i­dent and CEO on Ju­ly 5. In the in­ter­im, cur­rent CEO and co-founder Kevin Ap­pel­baum will con­tin­ue to serve in the role. Karbe makes his way to Bet­ter from My­ovant, where he was pres­i­dent and CFO. Ear­li­er in his ca­reer, Karbe was EVP and CFO of Ex­elix­is and worked as an in­vest­ment banker at Gold­man Sachs.

→ As Ak­ili In­ter­ac­tive preps com­mer­cial launch for its AD­HD video game ther­a­py En­deav­or­Rx in the fall, the com­pa­ny is mak­ing some room on its lead­er­ship team for com­mer­cial vet­er­an Matt Franklin as pres­i­dent and COO to help pave the way. Franklin most re­cent­ly served as gen­er­al man­ag­er of the pre­ci­sion on­col­o­gy busi­ness at Ex­act Sci­ences and be­fore that, was chief com­mer­cial of­fi­cer at Thrive Ear­li­er De­tec­tion. Ear­li­er in his ca­reer, Franklin was CBO for ArcherDX and SVP of glob­al mar­ket­ing and clin­i­cal prod­uct strat­e­gy at Foun­da­tion Med­i­cine.

Lu­ca Sca­vo

Cel­lec­tis nat­ur­al killer part­ner Cy­tovia, which took the SPAC route to Nas­daq with Isle­worth Health­care Ac­qui­si­tion in April, has pegged Lu­ca Sca­vo as CFO and James Priour as chief prod­uct of­fi­cer. Peer Re­view just re­port­ed last week that Sca­vo bolt­ed Evelo Bio­sciences af­ter a year as fi­nance chief, and he’s a Roche/Genen­tech vet who was CFO of Roche Di­ag­nos­tics North Amer­i­ca from 2019-21. Priour spent 11 years at Am­gen be­fore his ap­point­ment as SVP, com­mer­cial at Zymeworks in April 2020, even­tu­al­ly earn­ing a pro­mo­tion to chief com­mer­cial of­fi­cer.

Olivia Zetter

Bob Nelsen is dish­ing out sev­er­al pro­mo­tions at ARCH Ven­ture Part­ners: Ari Nowacek (to part­ner); Sean Kendall (to part­ner, Eu­rope); Corey Rit­ter (to prin­ci­pal); and Ni­lay Thakar (al­so to prin­ci­pal). ARCH is al­so bring­ing Olivia Zetter in­to the fold as a strate­gic ad­vi­sor and ven­ture part­ner. Zetter piv­ots to ARCH af­ter lead­ing gov­ern­ment af­fairs and AI strat­e­gy at Re­silience, which backed up the Brinks truck for a hefty $625 mil­lion Se­ries D this week.

Hu­bert Chen

→ It’s been a whirl­wind for Hu­bert Chen, so let’s break it all down: As 2021 drew to a close, Chen stepped down as CMO of Metacrine to take the same job at ADARx Phar­ma­ceu­ti­cals. But an­oth­er change of scenery awaits, this time as CSO and pres­i­dent of Forte Bio­sciences, which has been re­duced to a pi­anis­si­mo af­ter a flop with its lead atopic der­mati­tis can­di­date re­sult­ed in plum­met­ing shares. Be­fore he was with Metacrine, Chen was chief sci­en­tif­ic and med­ical of­fi­cer for Pfenex.

In­ci­den­tal­ly, ADARx has lined up An­drew Sea­cat as head of tox­i­col­o­gy, join­ing the RNA edit­ing brigade at the San Diego biotech af­ter his time at Zo­genix as se­nior di­rec­tor, phar­ma­col­o­gy and tox­i­col­o­gy. A for­mer prin­ci­pal sci­en­tist at Al­ler­gan, Sea­cat has al­so worked at La Jol­la Phar­ma­ceu­ti­cal as se­nior di­rec­tor, pre­clin­i­cal de­vel­op­ment.

Don’t call him an un­der­dog: Rudy Howard has been ap­point­ed as CFO of Hous­ton-based metasta­t­ic dis­ease play­er Ar­a­vive. Howard most re­cent­ly held the same po­si­tion at vTv Ther­a­peu­tics and SciQuest, and he has al­so served as SVP and CFO at MDS Phar­ma Ser­vices.

John Huynh

→ Led by ex-Forty Sev­en chief Mark Mc­Camish and hav­ing se­cured a $77 mil­lion Se­ries A in Jan­u­ary 2021, San Diego on­colyt­ic virus biotech IconOVir has ap­point­ed John Huynh as its first chief tech­nol­o­gy of­fi­cer. Be­fore his re­cent year-long run as SVP of tech­ni­cal op­er­a­tions at Ring Ther­a­peu­tics, Huynh was PTC Ther­a­peu­tics’ VP of gene ther­a­py tech­ni­cal op­er­a­tions.

An­drew San­dler

→ A cou­ple weeks ago, the FDA lift­ed the par­tial clin­i­cal hold on Alpine Im­mune Sci­ences’ com­bo tri­al with dav­o­ceti­cept and Keytru­da, and the Mitch Gold-led biotech will now wel­come An­drew San­dler as CMO on Aug. 17. San­dler had been CMO of Kiadis, which Sanofi bought for $358 mil­lion in No­vem­ber 2020 to beef up its NK ca­pa­bil­i­ties. A for­mer on­col­o­gy ex­ec at Bay­er, San­dler was al­so CMO at Spec­trum Phar­ma­ceu­ti­cals and Den­dreon. The FDA put up the stop sign on the tri­al in March af­ter a pa­tient death that was “at­trib­uted to car­dio­genic shock.”

→ Over at San Car­los, CA-based can­cer biotech Apex­i­gen, William Duke has signed on as CFO. Duke joins Apex­i­gen from the re­cent­ly shut­tered Kalei­do Bio­sciences, where he al­so served as CFO. He has al­so served in the same po­si­tion at Pul­ma­trix and Va­ler­i­tas.

Hatem Az­im

→ ADC-mind­ed Emer­gence Ther­a­peu­tics, try­ing to chal­lenge the Astel­las/Seagen drug Pad­cev with a Se­ries A near­ing $100 mil­lion back in De­cem­ber, has ap­point­ed Hatem Az­im as CMO. Most re­cent­ly, Az­im was head of on­col­o­gy, ear­ly clin­i­cal de­vel­op­ment at French phar­ma Pierre Fab­re. Be­fore that, he was VP, head of clin­i­cal de­vel­op­ment at In­nate Phar­ma.

Alexan­dra Kropo­to­va

→ The Omi­cron vari­ant forced the NIH to pull the plug on en­roll­ment for the AC­TIV-2 Phase III tri­al in­volv­ing SAB Bio­ther­a­peu­tics’ poly­clon­al an­ti­body, and three months lat­er, the Sioux Falls, SD biotech has named Alexan­dra Kropo­to­va as CMO. Kropo­to­va end­ed her eight-year as­so­ci­a­tion with Sanofi by serv­ing as VP, strat­e­gy & strate­gic plan­ning head, North Amer­i­can med­ical af­fairs be­fore leav­ing in 2016 for Te­va, where she was ther­a­peu­tic area head, glob­al spe­cial­ty R&D.

Michael Gold­stein

→ Oph­thal­mol­o­gy start­up Au­ri­on Biotech, which snagged a nice $120 mil­lion ear­li­er this year in a bid to scale cell ther­a­py for a form of blind­ness, has waved in Michael Gold­stein as pres­i­dent and CMO. Pri­or to his new role, Gold­stein was pres­i­dent and CMO of Oc­u­lar Ther­a­peu­tix and CMO of Ap­plied Ge­net­ic Tech­nolo­gies Corp. Ear­li­er in his ca­reer, Gold­stein was with Eleven Bio­ther­a­peu­tics, where he held a num­ber of roles, in­clud­ing CMO and VP of clin­i­cal re­search.

Dustin Haines

→ While Gilead cel­e­brates its 10-year an­niver­sary in Asia, the com­pa­ny has brought aboard Dustin Haines as VP, gen­er­al man­ag­er, Asia 5. Haines will be re­spon­si­ble for dri­ving the busi­ness de­vel­op­ment of HIV, vi­ral he­pati­tis in­clud­ing he­pati­tis B, C and D, as well as Gilead’s com­mit­ment to en­hance pub­lic health and com­mu­ni­ty im­pact in the Asia 5 mar­kets: Hong Kong, Sin­ga­pore, South Ko­rea, Tai­wan and Malaysia. Haines hails from Next Sci­ence, where he was CCO. Pri­or to that, Haines spent over a decade at Vi­iV Health­care (pres­i­dent and gen­er­al man­ag­er for Japan) and GSK.

→ Liv­er dis­ease-fo­cused Inipharm has brought on Chuhan Chung as CMO. Chung joins the com­pa­ny from Gilead, where he served as ex­ec­u­tive di­rec­tor and glob­al de­vel­op­ment lead and was re­spon­si­ble for clin­i­cal stud­ies in NASH and pri­ma­ry scle­ros­ing cholan­gi­tis. Pri­or to Gilead, Chung was an as­so­ciate pro­fes­sor at Yale Uni­ver­si­ty School of Med­i­cine, sec­tion of gas­troen­terol­o­gy & he­pa­tol­ogy.

Sara Weymer

→ Tak­ing aim at ex­tra­chro­mo­so­mal DNA (ecD­NA) to treat can­cer, Bound­less Bio has in­tro­duced Sara Weymer as VP of clin­i­cal op­er­a­tions. From 2016-21, Weymer led clin­i­cal op­er­a­tions at Fate Ther­a­peu­tics, whose iP­SC-de­rived nat­ur­al killer ther­a­pies have run in­to dura­bil­i­ty is­sues that sound the alarm bells but don’t nec­es­sar­i­ly spell doom. Ear­li­er in her ca­reer, Weymer was a se­nior clin­i­cal tri­al man­ag­er at Bio­gen.

→ AAV gene ther­a­py out­fit Ap­plied Ge­net­ic Tech­nolo­gies Cor­po­ra­tion has two ap­point­ments to an­nounce this week: Ed­uar­do Ja­cobo as SVP of GMP man­u­fac­tur­ing and David Ja­cobs as SVP of clin­i­cal re­search and med­ical af­fairs. Pri­or to join­ing AGTC, Ja­cobo ran GMP gene man­u­fac­tur­ing at Sang­amo, and he has al­so held nu­mer­ous man­u­fac­tur­ing po­si­tions at Am­gen and Eli Lil­ly. Ja­cobs comes to AGTC af­ter lead­ing clin­i­cal pro­grams at Bio­gen and Dai­ichi Sankyo.

Bri­an Stam­per

→ On the cusp of a Phase III tri­al with its den­drit­ic cell ther­a­py ITI-1000 for glioblas­toma mul­ti­forme, Im­mu­nom­ic Ther­a­peu­tics has se­lect­ed Bri­an Stam­per as VP, cell ther­a­py op­er­a­tions. A vet­er­an of Eli Lil­ly and As­traZeneca Bi­o­log­ics, Stam­per had a short run at Lon­za be­fore his most re­cent post as se­nior di­rec­tor of man­u­fac­tur­ing at Kite.

Al­fre­do Barón

→ CNS-fo­cused Neu­rax­pharm Group has tapped Al­fre­do Barón as the new coun­try man­ag­er of Neu­rax­pharm Spain, tak­ing over for Javier Mer­cadé — who has been ap­point­ed head of growth mar­kets. Barón joins Neu­rax­pharm from Almi­rall, where he most re­cent­ly served as EVP of glob­al com­mer­cial op­er­a­tions and CCO. Be­fore his most re­cent role at Almi­rall, Barón was di­rec­tor of sales and mar­ket­ing man­ag­er, cor­po­rate man­ag­ing di­rec­tor for south and east­ern Eu­rope and EVP and man­ag­ing di­rec­tor of Eu­rope for the com­pa­ny.

→ Da­ta man­age­ment out­fit Dot­mat­ics, which was snapped up by In­sight­ful Sci­ence last March, has named Lar­ry Samuel­son as chief le­gal of­fi­cer and Neil Frye as chief peo­ple of­fi­cer. Samuel­son most re­cent­ly served as SVP, gen­er­al coun­sel and cor­po­rate sec­re­tary of Cvent, while Frye is the for­mer chief peo­ple of­fi­cer of Al­to Phar­ma­cy and has pre­vi­ous­ly held roles at Drop­box, Google and Ac­cen­ture.

→ Duarte, CA-based Pro­lac­ta Bio­science has reeled in David Stein­berg as CFO. Stein­berg joins with ex­pe­ri­ence from pre­vi­ous stints at Jef­feries (man­ag­ing di­rec­tor) and Deutsche Bank un­der his belt.

Seth Van Voorhees

→ The board of di­rec­tors at NRx Phar­ma­ceu­ti­cals has re­cruit­ed Seth Van Voorhees as CFO and trea­sur­er. Van Voorhees hops aboard from PDS Biotech­nol­o­gy, where he al­so wore the CFO hat. Pri­or to that, he served a 10-year gig as CFO for Re­search Fron­tiers and for Amer­i­can Pa­cif­ic. Ear­li­er in his ca­reer, Van Voorhees served at Mer­rill Lynch, UBS War­burg and Wasser­stein Perel­la.

→ Cam­bridge, UK-based Metri­on Bio­sciences has ap­point­ed Benedet­ta Mon­tagni­ni as head of Eu­ro­pean busi­ness de­vel­op­ment. Mon­tagni­ni pre­vi­ous­ly served as busi­ness de­vel­op­ment man­ag­er at Eu­rofins Dis­cov­ery and Dis­cov­eRx. Be­fore that, Mon­tagni­ni was ac­count man­ag­er for the in­dus­tri­al bio­pro­cess­ing di­vi­sion at In­vit­ro­gen.

Kathryn Boor

Putting on a unit­ed front last month with oth­er Duchenne drug­mak­ers on why safe­ty prob­lems have dogged the in­di­ca­tion, Sarep­ta has added Michael Cham­bers and Kathryn Boor to its board of di­rec­tors. Cham­bers co-found­ed and was the long­time CEO of Alde­vron, and Boor is the dean of Cor­nell’s grad­u­ate school as well as vice provost for grad­u­ate ed­u­ca­tion.

Bahi­ja Jal­lal’s Im­muno­core has ap­point­ed Sid­dharth Kaul to the board of di­rec­tors. The re­tired Kaul last served as group trea­sur­er and head of busi­ness plan­ning and analy­sis at No­var­tis in 2021, where he spent 17 years of his ca­reer in such roles as CFO, phar­ma Eu­rope and CFO, phar­ma US.

Gre­go­ry Fiore

→ Like Hall of Fame col­lege bas­ket­ball coach Roy Williams sub­bing out an en­tire line­up, Brook­lyn Im­munoTher­a­peu­tics is putting new board mem­bers on the floor af­ter last week’s CEO change. In­ter­im chief Matt An­gel leads the list of names, fol­lowed by Exacis Bio­ther­a­peu­tics CEO Gre­go­ry Fiore, Pur­chase Cap­i­tal founder Nicholas Singer and Homer City Hold­ings chair­man and CEO Bill Wexler. Gone are Erich Mohr, Den­nis Langer, Heather Red­man, and Erin En­right, ef­fec­tive June 5.

→ With bil­lion­aire Ric Kayne sus­pend­ing his at­tempt to over­haul the board of di­rec­tors, Seat­tle Alzheimer’s biotech Athi­ra Phar­ma is mov­ing for­ward with a new sci­en­tif­ic ad­vi­so­ry board. Chaired by Athi­ra CMO Hans Moe­bius, the board will con­sist of An­ton Porsteins­son, John Olich­ney, Mar­wan Sab­bagh, Lon Schnei­der, Pierre Tairot and Paul Win­ner.

Janet Loes­berg

Am­brx Bio­phar­ma has boost­ed its board of di­rec­tors with Blue­print Med­i­cines SVP of glob­al med­ical af­fairs Janet Loes­berg. A 12-year Bris­tol My­ers Squibb vet, Loes­berg was briefly the VP, head of port­fo­lio and project man­age­ment, R&D for J&J’s Janssen.

Robert Hariri’s Celu­lar­i­ty has elect­ed for­mer Kite head of US com­mer­cial Di­ane Parks to the board of di­rec­tors. Parks adds the cell ther­a­py biotech to her list of board re­spon­si­bil­i­ties, which in­cludes posts at Cal­lid­i­tas Ther­a­peu­tics, CTI Bio­Phar­ma and Ku­ra On­col­o­gy.

Saira Ra­masas­try

Life Sci­ences Ad­vi­so­ry man­ag­ing part­ner Saira Ra­masas­try has been giv­en a seat on the board of di­rec­tors at Mirum Phar­ma­ceu­ti­cals. This is the lat­est in a string of cur­rent board ap­point­ments for Ra­masas­try at Vir, Glen­mark, Day One Bio­phar­ma­ceu­ti­cals and Ak­ou­os.

→ Cys­tic fi­bro­sis play­er Sion­na Ther­a­peu­tics has made room for Paul Clan­cy on the board of di­rec­tors. The for­mer CFO of Alex­ion (2017-19) and Bio­gen (2007-17) is on the boards of In­cyte, Ex­act Sci­ences and Xilio Ther­a­peu­tics.

Jen­nifer Zachary has clinched a spot on the board of di­rec­tors at Rockville, MD-based Re­genxbio, which has been in a patent squab­ble over Zol­gens­ma with No­var­tis. Zachary has been Mer­ck’s gen­er­al coun­sel since April 2018.

Paul Hudson, Sanofi CEO (Cyril Marcilhacy/Bloomberg via Getty Images)

FDA side­lines Paul Hud­son's $3.7B MS drug af­ter es­tab­lish­ing link to liv­er dam­age

One of Sanofi CEO Paul Hudson’s top picks in the pipeline — picked up in a $3.7 billion buyout 2 years ago — has just been sidelined in the US by a safety issue.

The pharma giant put out word early Thursday that the FDA has put their Phase III studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold, halting enrollment and suspending dosing for patients who have been on the drug for less than 60 days. Patients who have completed at least 60 days of treatment can continue therapy as researchers explore a “limited” — but unspecified in Sanofi’s statement — number of cases of liver injury.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

Phar­ma re­acts to post-Roe; Drug­mak­ers beef up cy­ber de­fense; Boehringer, Roche qui­et­ly axe drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

As a reminder, we are off on Monday for the Fourth of July. I hope this recap will kick off your (long) weekend well and that the rest of it will be just what you need. See you next week for a shortened edition!

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

Eric Hughes, incoming Teva EVP of global R&D and CMO

Te­va chief raids Ver­tex for his new glob­al head of re­search and de­vel­op­ment

Teva CEO Kåre Schultz has found his new R&D chief and CMO in Vertex’s ranks.

The global generics giant, which has some 3,500 staffers in the R&D group, has named Eric Hughes to the top research spot in the company. He’ll be replacing Hafrun Fridriksdottir, who held the role for close to five years, on Aug. 1.

Hughes hasn’t been at Vertex for long, though. He jumped from Novartis less than a year ago, after heading the immunology, hepatology & dermatology global development unit. Before that, he completed a five-year stint as head of early clinical research for the specialty discovery medicine department in the exploratory clinical & translational research group at Bristol Myers Squibb, according to his LinkedIn profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

#BIO22: Man­ag­ing a biotech in tur­bu­lent times. 'There's a per­fect shit­show out there'

On Tuesday, June 14, Endpoints News EIC John Carroll sat down with a group of biotech execs to discuss the bear market for industry stocks and how they were dealing with it. Here’s the conversation, which has been lightly edited for brevity.

Martin Meeson, sponsor opening:

Thank you, John. Hello everyone. My name’s Martin Meeson, I’m the CEO of Fujifilm Diosynth. For those of you who don’t know Fujifilm Diosynth, we operate in the development of clinical and commercial product scale up, we have facilities in Europe and the US, and around about 4,000 employees. We run on average about 150 programs, so when it comes to managing in turbulent times over the last two years, we’ve had quite a lot of experience of that. Not just keeping the clinical pipelines and the commercial pipelines open, but also our response to the pandemic and the molecules that we’ve had within there. One of the phrases that I coined probably about a year ago when we were talking at JP Morgan, was I talked about managing through turbulent times. Well, it’s become the fact that we are not managing and leading through these times, we are managing in them, which is why that’s really the purpose of and the topic that we’ve got today.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amgen's taking social media followers around the globe as it introduces the many different

From Tam­pa to Mu­nich, Am­gen’s ‘Places’ cam­paign in­tro­duces its lo­ca­tions around the world

Amgen is taking social media followers around the world with its latest corporate campaign. Called “Places of Amgen,” the twice monthly posts highlight the biopharma’s different offices and sites – and the people who work there.

Each post runs on LinkedIn, Facebook and Instagram with details about the work Amgen does in that location, when it was established, comments from people who work there and other interesting facts. The most recent one about Paris, France, for example, notes that Amgen France last year signed a French association charter committed to the inclusion of LBGT+ people in the workplace.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

On Friday, Lonza announced plans to construct a large-scale commercial drug product fill and finish facility in the town of Stein, Switzerland.

Lon­za to in­vest $500M+ on fill-fin­ish fa­cil­i­ty on its home turf

Lonza has been expanding its reach across the globe, bringing sites in China and the US online this year, but now they are looking closer to home for their next major investment.

The Swiss manufacturer on Friday announced plans to construct a large-scale commercial drug fill and finish facility in the town of Stein, Switzerland. The new facility will be delivered through an investment of approximately CHF 500 million, or $519 million, and is expected to be completed in 2026. The facility will also be constructed on the same campus as Lonza’s current clinical drug product facility.

Credit: Shutterstock

Bio­haven takes mi­graine cam­paign to pa­tients' Twit­ter feeds, months ahead of Pfiz­er takeover

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.

Oncologists on Twitter are talking up ASCO studies, health equity and burnout, according to new deep dive research from Harris Poll (via Shutterstock)

What’s been on in­flu­en­tial on­col­o­gist­s' minds? Most­ly AS­CO, but al­so health eq­ui­ty, ac­cord­ing to new Har­ris Poll re­search

Over the past few months, oncologists have been talking a lot about the ASCO conference. Not surprising considering its import and the study data presented, but what may be less expected is the second most talked about topic of health equity.

That’s according to data from The Harris Poll and the new expert network the researcher is building out. While the company has been doing deep data dives into specific health issues or conditions for pharma clients, it’s now monitoring influencer networks of therapy area specialists to find out what experts are really thinking about.

Emer Cooke, ICRMA chair (AP Photo/Geert Vanden Wijngaert)

ICM­RA to launch sev­er­al reg­u­la­to­ry pi­lot pro­grams cen­tered around man­u­fac­tur­ing in­spec­tions

As regulatory agencies look to catch up on inspections amid the Covid-19 pandemic, ICMRA is unveiling several pilot programs to address industry applications and inspections.

ICMRA, which is made up of the world’s top drug regulators, is launching multiple pilot programs, including two regulatory pilots addressing facility inspections for chemistry and manufacturing controls (CMC) and post-approval change (PAC) submission assessments and related regulatory actions.